A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety and Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism and Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs MDR 103 (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Medeor Therapeutics
- 11 Apr 2019 Planned initiation date changed from 1 Aug 2018 to 31 Aug 2019.
- 11 Apr 2019 Status has been changed to not yet recruiting.
- 02 Oct 2018 Status changed from not yet recruiting to recruiting.